Advertisement
Table 1 Illustrative points system for the incremental-benefits variable
| Dimensions | Points (weights) |
|---|---|
| Lives saved, including ‘statistical’ lives (i.e. cure or reduced risk of death) | |
| None (or not yet known) | 0 |
| Few: 1-50 lives saved | 0.091 |
| Some: 51-250 lives saved | 0.192 |
| Many: 251-500 lives saved | 0.268 |
| Very many: > 500 lives saved | 0.343 |
| Life-prolongation benefits – in terms of increase in life expectancy and its quality-of-life, and number of patients affected | |
| None/Very small (or not yet known) | 0 |
| Small benefits | 0.053 |
| Medium benefits | 0.152 |
| Large benefits | 0.244 |
| Quality-of-life gains – in terms of baseline QoL, size of QoL gains and duration, and number of patients affected | |
| None/Very small (or not yet known) | 0 |
| Small QoL gains | 0.051 |
| Medium QoL gains | 0.138 |
| Large QoL gains | 0.217 |
| If this technology were not to be funded … | |
| Many/most patients will be able to pay for it themselves (privately) | 0 |
| Many/most patients will get an alternative treatment (less effective) already funded by government | 0.055 |
| Many/most patients will not receive any treatment for condition | 0.108 |
| Other important social or ethical benefits, e.g. targeted to children/minorities; reduces health gaps, etc | |
| None/Very small (or not yet known) | 0 |
| Yes | 0.087 |
